Skip to main content

Table 1 Comparison between baseline and follow-up values of lab investigations of patients

From: Sofosbuvir and daclatasvir are safe and effective in treatment of recurrent hepatitis C virus in Egyptian patients underwent living donor liver transplantation

  Baseline During treatment Follow-up
1 month p value EOT p value 3 months p value 6 months p value 9 months p value
Hemoglobin (g/dl) 11.5 ± 0.91 11.2 ± 0.77 0.013 11.4 ± 0.75 0.55 11.3 ± 0.69 0.45 11.3 ± 0.43 0.21 11.1 ± 0.58 0.018
Platelets 153.6 ± 39.4 184.1 ± 59.1 0.003 160.6 ± 36.2 0.43 157.3 ± 38.9 0.69 191.8 ± 36.2 < 0.001 179.7 ± 36.2 0.005
ALT (IU/l) 45.9 ± 15.2 35.8 ± 10.4 0.001 37.6 ± 7.9 0.004 34.3 ± 11.1 < 0.001 33.7 ± 12.4 < 0.001 32.6 ± 11.1 < 0.001
AST (IU/l) 36.8 ± 13.4 35.0 ± 7.1 0.35 33.7 ± 12.4 0.33 36.9 ± 8.6 0.98 38.5 ± 10.5 0.49 37.6 ± 7.9 0.64
AFP (ng/ml) 28.4 ± 17.05 28.9 ± 17.6 0.95 31.4 ± 18.9 0.54 35.3 ± 20.2 0.08 26.6 ± 14.8 0.64 22.6 ± 13.02 0.13
Albumin (g/dl) 3.23 ± 0.39 3.23 ± 0.35 0.49 3.6 ± 0.38 0.001 3.5 ± 0.42 0.019 3.4 ± 0.39 0.04 3.5 ± 0.45 0.004
ALP (IU/l) 132.8 ± 45.1 107.6 ± 11.5 0.002 103.5 ± 48.2 0.002 99.3 ± 14.9 < 0.001 107.6 ± 11.5 0.002 99.3 ± 14.9 < 0.001
Bilirubin (mg/dl) 1.07 ± 0.14 1.03 ± 0.15 0.28 0.99 ± 0.11 0.003 1.3 ± 1.7 0.08 0.99 ± 0.16 0.04 0.99 ± 0.20 0.045
Urea (mg/dl) 45.3 ± 16.9 40.0 ± 10.6 0.18 34.9 ± 10.7 0.005 34.3 ± 9.04 0.001 34.8 ± 7.7 0.005 34.6 ± 7.4 0.002
Creatinine (mg/dl) 0.91 ± 0.33 0.92 ± 0.25 0.99 0.93 ± 0.159 0.72 0.93 ± 0.16 0.52 0.96 ± 0.23 0.43 0.95 ± 0.24 0.65
INR 1.06 ± 0.13 0.92 ± 0.19 < 0.001 1.3 ± 1.6 0.63 0.93 ± 0.19 0.002 1.04 ± 0.14 0.36 1.03 ± 0.22 0.34
  1. EOT end of treatment, ALT alanine aminotransferase, AST aspartate aminotransferase, AFP alpha fetoprotein, ALP alkaline phosphatase